These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21921040)

  • 1. EZH2 mutational status predicts poor survival in myelofibrosis.
    Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM
    Blood; 2011 Nov; 118(19):5227-34. PubMed ID: 21921040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
    Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
    Tefferi A; Pardanani A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Gangat N; Finke CM; Schwager S; Mullally A; Li CY; Hanson CA; Mesa R; Bernard O; Delhommeau F; Vainchenker W; Gilliland DG; Levine RL
    Leukemia; 2009 May; 23(5):905-11. PubMed ID: 19262601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
    Masarova L; Alhuraiji A; Bose P; Daver N; Pemmaraju N; Cortes J; Pierce S; Kantarjian H; Verstovsek S
    Eur J Haematol; 2018 Mar; 100(3):257-263. PubMed ID: 29226426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
    Tefferi A; Lasho TL; Abdel-Wahab O; Guglielmelli P; Patel J; Caramazza D; Pieri L; Finke CM; Kilpivaara O; Wadleigh M; Mai M; McClure RF; Gilliland DG; Levine RL; Pardanani A; Vannucchi AM
    Leukemia; 2010 Jul; 24(7):1302-9. PubMed ID: 20508616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.
    Byun JM; Song S; Koh Y; Yoon SS; Kim D
    Anticancer Res; 2019 Nov; 39(11):6273-6282. PubMed ID: 31704857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.
    Nischal S; Bhattacharyya S; Christopeit M; Yu Y; Zhou L; Bhagat TD; Sohal D; Will B; Mo Y; Suzuki M; Pardanani A; McDevitt M; Maciejewski JP; Melnick AM; Greally JM; Steidl U; Moliterno A; Verma A
    Cancer Res; 2013 Feb; 73(3):1076-85. PubMed ID: 23066032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
    Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
    Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
    Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
    Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
    Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
    Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations and prognosis in primary myelofibrosis.
    Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
    Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
    Masarova L; Verstovsek S
    Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
    Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
    Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
    Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
    Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostication in MF: from CBC to cytogenetics to molecular markers.
    Zhou A; Oh ST
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.
    Abdel-Wahab O; Pardanani A; Patel J; Wadleigh M; Lasho T; Heguy A; Beran M; Gilliland DG; Levine RL; Tefferi A
    Leukemia; 2011 Jul; 25(7):1200-2. PubMed ID: 21455215
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition.
    Sashida G; Wang C; Tomioka T; Oshima M; Aoyama K; Kanai A; Mochizuki-Kashio M; Harada H; Shimoda K; Iwama A
    J Exp Med; 2016 Jul; 213(8):1459-77. PubMed ID: 27401345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.